PPI 1019

Drug Profile

PPI 1019

Alternative Names: Apan

Latest Information Update: 23 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Praecis Pharmaceuticals
  • Class Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 27 May 2005 Suspended - Phase-I/II for Alzheimer's disease in USA (IV)
  • 08 Feb 2005 PPI 1019 (Apan™) is available for licensing beyond phase I development (http://www.praecis.com)
  • 31 Jan 2005 Praecis Pharmaceuticals has initiated enrolment in the multiple dose escalation, phase I/IIa trial for Alzheimer's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top